Kymeta Goshawk™ u8 Enters Global Market as European Allies Face Growing Defense Pressures
10.3.2025 13:00:00 CET | Business Wire | Press Release
Kymeta, a world leader in flat-panel satellite antenna technology, announces today it is accepting orders for its Goshawk u8 user terminal, designed specifically for government and global ministry of defense. With the growing need for satellite network flexibility and open network architecture that ensure secure, sovereign defense operations, the Goshawk u8 offers a critical solution at a time when allied nations prioritizing secure, resilient, and rapidly deployable communications on the move.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310979046/en/
Goshawk u8 - secure communications for government and global forces (Photo: Business Wire)
The Kymeta Goshawk u8 delivers resilient and flexible, multi-orbit, multi-network satellite communications in a single terminal. Combining Low Earth Orbit (LEO) and Geostationary Orbit (GEO) satellite technologies alongside cellular connectivity, it allows for improved responsiveness to enable maneuver warfare tactics, such as rapid, focused and unexpected actions that can shatter an enemy’s cohesion.
As sovereign nations look to prioritize greater control over critical satcom infrastructure to stay ahead of emerging threats, the Goshawk u8, which has been designed to support data-centric, cloud-enabled operations, will ensure defense and government users remain connected whenever and wherever they need it most.
Rick Bergman, CEO and President of Kymeta, stated: “At Kymeta, we are relentless in our mission to empower those who protect and serve nations and communities. In a world where secure and independent communications are non-negotiable, the Goshawk u8 will provide government and defense users the freedom to operate with confidence. The Goshawk u8 comes at a time of heightened global demand for trusted, sovereign communications solutions, as governments, including the DoD and defense organizations, look to strengthen operational resilience amid an increasingly complex security landscape.”
Partner Testing
The Goshawk has been in partner trials, receiving highly positive feedback. Customers are experiencing firsthand the innovation and value our solution delivers. This momentum is further fueled by surging demand from the DoD and global militaries. As a result, demand for its cutting-edge Intelligent Communication Platforms (ICPs) continues to grow. These ICPs are setting a new standard for secure, reliable connectivity in mission-critical environments.
About the Goshawk u8 terminal
The Goshawk u8, which is easy to install and engineered for seamless mobility, is a fully customizable, compact and lightweight solution that integrates effortlessly across diverse vehicles and vessels. It provides reliable, network-redundant connectivity on the move to meet mission-critical demands and real-time operations for multinational defense operations.
The new antenna provides jamming mitigation for GNSS-denied operations, effortlessly integrating with existing networks. It supports high-bandwidth applications, enabling global defense units to access video streaming, data transmission and voice communication with minimal interruptions, even in remote or mobile scenarios.
The electronically steered antenna (ESA) has a user-friendly interface making connectivity quick and easy and its metamaterial casing and compact, lightweight profile enhances durability and reliability in harsh conditions.
As Kymeta accelerates its global expansion, it is set to push the boundaries of its product portfolio - and the Goshawk u8 is the latest drive for the company to do this. Delivering next-generation solutions that redefine satellite and hybrid communications for defense, government and commercial markets, Kymeta ensures that customers stay ahead in an increasingly volatile and connected world.
About Kymeta:
Kymeta revolutionizes satellite communications through Intelligent Communications Platforms (ICPs). Founded in 2012 and headquartered in Redmond, Washington, Kymeta leverages cutting-edge metamaterial-based science to engineer, manufacture and deliver resilient connectivity and enhanced situational awareness for critical, mobile applications. Backed by U.S. and international patents, our electronically steered flat-panel antennas enable seamless communications on the move. With software-defined solutions, hybrid multi-network capabilities, and edge processing, we integrate satellite and cellular networks, ensuring continuous connectivity in challenging environments. Kymeta solutions serve government, military, maritime, transport, and public safety clients worldwide, providing uninterrupted connectivity and spatial intelligence anywhere, anytime. With over 150 patents, Kymeta is shaping the future of global communications, dedicated to delivering reliable, efficient, and intelligent connectivity solutions for an increasingly mobile and connected world.
Kymeta is a privately held company based in Redmond, Washington. For more information, visit kymetacorp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310979046/en/
Contacts
For briefings, interviews or further information please contact:
361 Communications
Rachel Bowden +44 7769900538 | rachel@361communications.com
Emma-Jo Jones +44 7796934230 | emmajo@361communications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom